This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for the treatment of cancerous cell growth mediated by RAF kinase, comprising administering a compound of Formula I:

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: $-L-(M-L^1)_q$, where L is a 5 or 6 membered cyclic structure bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 heteroatoms which are ~~members of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 heteroatoms which are ~~members of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur,

wherein L^1 is substituted by at least one ~~substituent selected from the group consisting~~ of $-SO_2R_x$, $-C(O)R_x$ or ~~and~~ $-C(NR_y)R_z$,

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and optionally halosubstituted, up to ~~per-halo~~ per-halosubstitution,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are N, S, or O ~~selected from N, S and O~~ and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituents of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and is

~~are~~ optionally substituted by halogen;

R_x is independently chosen from R_z moieties or is ~~R_z or~~ NR_aR_b where R_a and R_b are

a) independently

i) hydrogen,

ii) a carbon based moiety of up to 30 carbon atoms optionally containing one or more heteroatoms which are ~~selected from~~ N, S or ~~and~~ O and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are ~~selected from~~ N, S or ~~and~~ O and is ~~are~~ optionally substituted by halogen, or

iii) $-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are ~~selected from~~ N, S or ~~and~~ O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are ~~selected from~~ N, S or ~~and~~ O substituted by halogen, hydroxy or a carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the one or more substituents ~~substituent(s)~~ of the substituted C_1-C_5 divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or

more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen;

where B is substituted, L is substituted or L^1 is additionally substituted, the one or more substituents are ~~selected from the group consisting of~~ halogen, up to per-halosubstitution ~~per-halo~~, and W_n ~~n~~, where n is 0-3;

wherein each W is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, or a ~~and~~ carbon based moeity ~~moieties~~ of up to 24 carbon atoms[~~,~~] optionally containing one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and optionally substituted by one or more substituents which are independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ or ~~and~~ halogen up to per-halosubstitution ~~per-halo~~; with each R^7 independently being ~~selected from~~ H or a carbon based moiety of up to 24 carbon atoms[~~,~~] optionally containing one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and optionally substituted by halogen,

wherein Q is -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are ~~members selected from the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, which is optionally substituted by halogen, up to per-halosubstitution, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$ $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, or ~~and~~ a carbon based moiety of up to 24 carbon atoms[~~,~~] optionally containing one or more heteroatoms which are N, S, or O ~~selected from N, S and O~~ and optionally substituted by one or more substituents which are ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, or ~~and~~ $-NR^7C(O)OR^7$, with each R^7 being independently as defined above.

2. (Currently Amended) A method as in claim 1 wherein:

R_y is hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C_{7-24} aralkyl, C_{7-24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, substituted C_6 -C_{14} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, substituted C_{7-24} alkaryl or substituted C_7-C_{24} aralkyl, where R_y is a substituted group, it is substituted by halogen up to ~~per halo~~ per-halosubstitution,

R_z is hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 which are N, S or O heteroatoms, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3 -C_{12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from, S, N and O~~, C_{7-24} alkaryl , C_{7-24} aralkyl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_6-C_{14} aryl, substituted C_3 -C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from S, N and O~~, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from S, N and O~~, substituted C_{7-24} alkaryl or substituted C_7-C_{24} aralkyl where R_z is a substituted group, it is substituted by halogen up to per-halosubstitution ~~per halo~~, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted ~~per halo~~ alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted ~~per halo~~ aryl, C_3-C_{12} halosubstituted cycloalkyl up to per-halosubstituted per-halo cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted ~~per halo~~ hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted ~~per halo~~ alkaryl, and -C(O)R_g,

R_a and R_b are,

a) independently

i) hydrogen,

ii) a carbon based moiety which is ~~selected from tee group consisting of~~ C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, ~~C_{3-12}~~ C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S, O ~~selected from N, S and O~~, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_a or R_b are substituted, the substituents are ~~substituted by~~ halogen up to per-halosubstituted ~~per-halo~~, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted ~~per halo~~ alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted ~~per halo~~ aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, up to per-halosubstituted ~~per halo~~ cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted ~~per halo~~ heteroaryl, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted ~~per halo~~ alkaryl, or ~~and~~ -$C(O)R_g$; or

iii) -$OSi(R_f)_3$ where R_f is hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{7-24} aralkyl, substituted C $_{1-10}$ alkyl, substituted C_1-C_{10} alkoxy, substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, substituted C_3-C_{12} heteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, S, and N~~, substituted C_{6-12} aryl, or ~~and~~ substituted C_{7-24} alkaryl,

where R_f is a substituted group it is substituted halogen up to per-halosubstitution ~~per halo~~, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O ~~selected from N, S and O~~, C_{1-10} alkoxy, C_{6-12} aryl, C_7 -C_{24} alkaryl, C_7 -C_{24} aralkyl, C_{1-6} halosubstituted alkyl up to per-halosubstituted ~~per halo~~ alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted ~~per halo~~ aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, up to per-halosubstituted ~~per halo~~ cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted ~~per halo~~ heteroaryl, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted C_7-C_{24} alkaryl up to per-halo substituted ~~per halo~~ alkaryl, or ~~and~~ -C(O)R_g,

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ with substituents which are ~~selected from the group consisting of~~ halogen up to per-halosubstitution ~~per halo~~, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C_{1-10} alkoxy, C_{6-12} aryl, C_7 -C_{24} alkaryl, C_7 -C_{24} aralkyl, halosubstituted C_{1-6} alkyl up to per-halosubstituted ~~per halo~~ alkyl, halosubstituted C_6-C_{12} aryl up to per-halosubstituted ~~per halo~~ aryl, halosubstituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, up to per-halosubstituted ~~per halo~~ cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted ~~per halo~~ heteroaryl, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted ~~per halo~~ alkaryl, or ~~and~~ -C(O)R_g,

or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5

members,

wherein the substituents of the substituted C_1-C_5 divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C_{1-10} alkoxy, C_{6-12} aryl, C_7 -C_{24} alkaryl, C_7 -C_{24} aralkyl, C_{1-6} halosubstituted alkyl up to per-halosubstituted ~~per halo~~ alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted ~~per halo~~ aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, up to per-halosubstituted ~~per halo~~ cycloalkyl, halosubstituted C_3-C_{12} heteroaryl ~~hetaryl~~ up to per-halosubstituted ~~per halo~~ heteroaryl, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted ~~per halo~~ alkaryl, or ~~and~~ -$C(O)R_g$,

where R_g is C_{1-10} alkyl; -CN, -CO_2R_d, -OR_d, -SR_d, -NO_2, -C(O) R_e, -NR_dR_e, -NR_d C(O)OR_e or ~~and~~ -NR_d C(O)R_e, or ~~and~~ R_d and R_e are independently ~~selected from the group consisting of~~ hydrogen, C_{1-10}, alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, C_{6-12} aryl, C_3- C_{12} hetaryl with 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~ and C_7 -C_{24} aralkyl, C_7 -C_{24} alkaryl, up to per-halosubstituted ~~per halo substituted~~ C_1-C_{10} alkyl, up to per-halosubstituted ~~per halo substituted~~ C_3 -C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, up to per-halosubstituted ~~per halo substituted~~ C_6 -C_{14} aryl, up to per-halosubstituted ~~per halo substituted~~ C_3 -C_{12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N, and S,~~ halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted ~~per halo~~ alkaryl, or ~~and~~ up to per-halosubstituted ~~per halo substituted~~ C_7-C_{24} aralkyl,

W is independently ~~selected from the group consisting of~~ -CN, -CO_2R^7, -$C(O)NR^7R^7$, -$C(O)$-R^7, -NO_2, -OR^7, -SR^7, -NR^7R^7, -$NR^7C(O)OR^7$, -$NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_7 -C_{24} aralkyl, C_3-C_{12} heteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, C_4-C_{23} alkheteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and~~ S, substituted C_1-C_{10} alkyl, substituted

C_1-C_{10} alkoxy, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkenoyl, substituted C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, substituted C_6-C_{12} aryl, substituted C_3-C_{12} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, substituted C_7-C_{24} aralkyl, substituted C_7-C_{24} alkaryl, substituted C_4-C_{23} alkheteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, or ~~and~~ -Q-Ar;

R^7 is independently ~~selected from~~ H, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C_6-C_{14} aryl, C_3-C_{13} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, C_7-C_{14} alkaryl, C_7 -C_{24} aralkyl, C_4-C_{23} alkheteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, up to per-halosubstituted C_6-C_{14} aryl, up to per-halosubstituted C_3-C_{13} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, up to per-halosubstituted C_7-C_{24} aralkyl, up to per-halosubstituted C_7-C_{24} alkaryl, or ~~and~~ up to per-halosubstituted C_4-C_{23} alkheteroaryl; and

each Z is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, - SR^7 $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, C_6-C_{14} aryl, C_3-C_{13} hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, C_7-C_{24} alkaryl, C_7 -C_{24} aralkyl, C_4-C_{23} alkheteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, substituted C_1-C_{10} alkyl, substituted C_1-C_{10} alkoxy, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkenoyl, substituted C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, substituted C_6-C_{12} aryl, substituted C_7-C_{24} alkaryl, substituted C_7-C_{24} aralkyl or ~~and~~ substituted C_4-C_{23} alkheteroaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~;

wherein if Z is a substituted group, the one or more substituents are ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, or ~~and~~ $-NR^7C(O)OR^7$.

3. (Currently Amended) A method as in claim 2 ~~1~~ wherein M is one or more bridging groups which are ~~selected from the group consisting of~~ -O-, -S-, -N(R^7)-, -(CH_2)$_m$-, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^7)-, -O(CH_2)$_m$- CHX^a-, -CX^a_2-, -S-(CH_2)$_m$- or ~~and~~ -N(R^7)(CH_2)$_m$-, where m= 1-3, X^a is halogen and $R^7$is as defined in claim 2 ~~1~~.

4. Cancelled

5. Cancelled

6. (Currently Amended) A method of claim 2 ~~1~~ wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by one or more substituents which are ~~a substituent selected from the group consisting of~~ halogen or ~~and~~ W_n ~~Wn~~ wherein W is as defined in claim 2 and n is 0-3 ~~and n are as defined in claim 1~~, a pyrimidinyl group substituted by one or more substituents which are halogen or W_n wherein ~~a substituent selected from the group constituting of halogen and Wn~~, ~~whereas~~ W is as defined in claim 2 and n is 0-3 ~~and n are as defined in Claim 1~~, or a substituted pyridyl group substituted by one or more substituents which are halogen or W_n ~~a substituent selected from the group consisting of halogen and Wn~~ wherein W is as defined in claim 2 and n is 0-3 ~~and n are as defined in claim 1~~.

7. (Currently Amended) A method of claim 91 ~~6~~ wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyrridyl group substituted 1 to 3 times by 1 or more substituents which are ~~selected from the group consisting of~~ -CN, halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -OH, up to per-halosubstituted ~~per-halo-substituted~~ C_1-C_{10} alkyl, up to per-halosubstituted ~~per-halo-substituted~~ C_1-C_{10} alkoxy or phenyl substituted by halogen up to per-halosubstitution ~~per-halo~~.

8. (Currently Amended) A method of claim 2 ~~1~~, wherein L, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members which are ~~selected from the group of heteroatoms consisting of~~ nitrogen, oxygen or ~~and~~ sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are ~~selected from the group consisting of~~ halogen or ~~and~~ W_n ~~Wn~~ wherein W is as defined in claim 2 and n is 0-3 ~~and n are as defined in claim 1~~.

9. (Currently Amended) A method of claim 91 ~~8~~, wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.

10. (Currently Amended) A method of claim 1, wherein said substituted cyclic moiety L^1 comprises pyridinyl ~~a 5-to-6-membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1-to-4 members selected from the group of heteroatoms consisting of~~ nitrogen, oxygen or ~~and~~ sulfur.

11. (Currently Amended) A method of claim 2, wherein said substituted cyclic moiety L^1 is ~~phenyl,~~ pyridinyl ~~or pyrimidinyl~~.

12. (Currently Amended) A method of claim 3, wherein said substituted cyclic moiety L^1 is ~~phenyl,~~ pyridinyl ~~or pyrimidinyl~~.

13. (Currently Amended) A method of claim 6, wherein said substituted cyclic moiety L^1 is ~~phenyl,~~ pyridinyl ~~or pyrimidinyl~~.

14. Cancelled

15. (Currently Amended) A method of claim 7, wherein said substituted cyclic moiety L^1 is ~~phenyl,~~ pyridinyl ~~or pyrimidinyl~~.

16. Cancelled

17. (Currently Amended) A method of claim 8, wherein said substituted cyclic moiety L^1 is ~~phenyl,~~ pyridinyl ~~or pyrimidinyl~~.

18. (Currently Amended) A method of claim 13, wherein M is one or more bridging groups which are ~~selected from the group consisting of~~ -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen up to per-halosubstitution ~~per halo~~.

19. (Currently Amended) A method of claim 15, wherein M is one or more bridging groups which are ~~selected from the group consisting of~~ -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen up to per-halosubstitution ~~per halo~~.

20. Cancelled

21. (Currently Amended) A method of claim 17, wherein M is one or more bridging groups which are ~~selected from the group consisting of~~ -O-, -S-, -N(R^7)-, -(CH_2)$_m$-, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^7)-, -O(CH_2)$_m$- CHX^a-, -CX^a_2-, -S-(CH_2)$_m$- or ~~and~~ -N(R^7)(CH_2)$_m$-, where m= 1-3, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing one or more heteroatoms which are N, S and O ~~selected from N, S and O~~ and optionally substituted by halogen up to per-halosubstitution ~~per halo~~.

22. Cancelled

23. Cancelled

24. Cancelled

25. Cancelled

26. Cancelled

27. (Currently Amended) A method of claim 21 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents which are ~~selected from the group consisting of~~ C_1-C_{10} alkyl, up to per-halosubstituted ~~per halo substituted~~ C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy and up to per-halosubstituted ~~per halo substituted~~ C_1-C_{10} alkoxy.

28. (Currently Amended) A method of claim 2~~1~~ wherein L^1 is substituted by -C(O)R_x.

29. Cancelled

30. Cancelled

31. Cancelled

32. (Currently Amended) A method of claim 2~~1~~ wherein L^1 is pyridinyl substituted

by -C(O)R_x ~~or $-SO_2R_x$~~, wherein R_x is NR_aR_b.

33. (Currently Amended) A method of claim 13 wherein L^1 is pyridinyl substituted by -C(O)R_x or $-SO_2R_x$, wherein R_x is NR_aR_b, and R_a and R_b are

a) independently

i) hydrogen,

ii) a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen, or

$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally contain ~~contains~~ one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ substituted by halogen, hydroxy or a carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituent ~~substituents~~ of the substituted C_1-C_5 divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, or a ~~and~~ carbon based substituent

~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S and O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen.

34. Cancelled

35. Cancelled

36. Cancelled

37. (Currently Amended) A method of claim 21 wherein L^1 is substituted by $-C(O)R_x$ or $-SO_2R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms [~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen.

38. (Currently Amended) A method for the treatment of cancerous cell growth mediated by RAF kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound of Formula I:

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: $-L-(M-L^1)_q$, where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, ~~M is a bridging group having at~~

~~least one atom,~~ q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 heteroatoms which are ~~members of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, and

B is a substituted or unsubstituted, phenyl, pyridyl or pyrimidinyl group ~~up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,~~

wherein L^1 is substituted by at least one substituent which is ~~selected from the group consisting~~ of $-SO_2R_x$, $-C(O)R_x$ or ~~and~~ $-C(NR_y)\ R_z$,

R_y is hydrogen or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are O, N or S, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl, ~~a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per-halo,~~

R_z is hydrogen or substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, or ~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

R_x is independently chosen from the R_z moieties or is ~~R_z or~~ NR_aR_b where R_a and R_b are

a) independently

i) hydrogen,

ii) C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are from N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_a or R_b is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O , C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, or ~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen,or~~

iii) -$OSi(R_f)_3$ where R_f is hydrogen or ~~a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~ C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O,

substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_f is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ substituted by halogen, or hydroxy or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the 5-7 member heterocyclic structure is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl; ~~or hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are halogen, hydroxy C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the C_1-C_5 divalent alkylene is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are ~~selected from the group consisting of~~ halogen, up to per-halosubstitution ~~per-halo~~, and W_n ~~Wn~~, where n is 0-3;

wherein each W is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy,

substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

wherein W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~-and- carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,~~

wherein Q is -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are ~~members selected from the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, which is optionally substituted by halogen, up to per-halosubstitution ~~per-halo~~, and is optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$ $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl,

substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where Z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

~~and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, and $-NR^7C(O)OR^7$, with R^7 as defined above;~~ and

wherein M is one or more bridging groups which are ~~selected from the group consisting of~~ -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, and X^a is halogen.

39. (Currently Amended) A method for the treatment of cancerous cell growth mediated by RAF kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound of Formula I:

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: $-L-(M-L^1)_q$, where L is a substituted or unsubstituted phenyl ~~pyridinyl~~ moiety bound directly to D, L^1 comprises a substituted phenyl, pyridinyl or pyrimidinyl moiety, ~~M is a bridging group having at least one atom,~~ q is an integer of from 1-3; and

B is a substituted or unsubstituted phenyl or pyridinyl ~~pyridine~~ group bound directly to D,

wherein L^1 is substituted by one or more substituents which are ~~at least one substituent selected from the group consisting of~~ ~~$-SO_2R_x$~~, $-C(O)R_x$ or ~~and~~ $-C(NR_y)R_z$,

R_y is hydrogen or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_y is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

~~a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and ;~~

R_z is hydrogen or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12}

halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

R_x is independently chosen from the R_z moieties or is ~~R_z or~~ NR_aR_b where R_a and R_b are

a) independently

i) hydrogen,

ii) C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_x is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

iii) -$OSi(R_f)_3$ where R_f is hydrogen or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are

N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_f is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, ~~a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~ or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ substituted by halogen, hydroxy or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the 5-7 member heterocyclic structure is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3

heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~ or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, ~~and~~ or a C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, $C_{3\text{-}10}$ cycloalkyl, $C_{2\text{-}10}$ alkenyl, $C_{1\text{-}10}$ alkenoyl, $C_{6\text{-}12}$ aryl, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, $C_{3\text{-}10}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{7\text{-}24}$ aralkyl, C_7-C_{24} alkaryl, substituted $C_{1\text{-}10}$ alkyl, substituted $C_{1\text{-}10}$ alkoxy, substituted $C_{3\text{-}10}$ cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted $C_{6\text{-}12}$ aryl, substituted $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, substituted $C_{7\text{-}24}$ aralkyl, or substituted $C_{7\text{-}24}$ alkaryl,

where the substituent on the C_1-C_5 divalent alkylene is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, $C_{1\text{-}10}$ alkyl, $C_{3\text{-}12}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, $C_{1\text{-}10}$ alkoxy, $C_{6\text{-}12}$ aryl, $C_{1\text{-}6}$ halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are ~~selected from the group consisting of~~ halogen, up to per-halosubstitution ~~per-halo~~, or ~~and~~ W_n ~~Wn~~, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, or C_1 -

C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

~~and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO_2R^7, -C(O)R^7, -C(O)NR^7R^7, -OR^7, -SR^7, -NR^7R^7, -NO_2, -$NR^7C(O)R^7$, -$NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,~~

wherein Q is -O-, -S-, -N(R^7)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^7)-, -O$(CH_2)_m$- CHX^a-, -CX^a_2-, -S-$(CH_2)_m$- or ~~and~~ -N(R^7)$(CH_2)_m$-, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are ~~members selected from the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, which is optionally substituted by halogen, up to per-halosubstitution ~~per-halo~~, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, -CO_2R^7, -C(O)R^7, -C(O)NR^7R^7, -NO_2, -OR^7, - SR^7 -NR^7R^7, -$NR^7C(O)OR^7$, -$NR^7C(O)R^7$, C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12}

hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where Z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl; and

~~and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of CN, CO_2R^7, COR^7, $C(O)NR^7R^7$, OR^7, SR^7, NO_2, NR^7R^7, $NR^7C(O)R^7$, and $NR^7C(O)OR^7$; and~~

wherein M is one or more bridging groups which are ~~selected from the group consisting of~~ -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, X^a is halogen.

40. Cancelled

41. Cancelled

42. Cancelled

43. (Currently Amended) A method as in claim 38 wherein substituents for B and L and additional substituents for L^1, are ~~selected from the group consisting of~~ C_1-C_{10} alkyl[,]up to per-halosubstituted ~~per halo substituted~~ C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy or ~~and~~ up to per-halosubstituted ~~per halo substituted~~ C_1-C_{10} alkoxy.

45. (Currently Amended) A method as in claim 39 wherein substituents for B and L and additional substituents for L^1, are ~~selected from the group consisting of~~ C_1-C_{10} alkyl[,] up to per-halosubstituted ~~per-halo-substituted~~ C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy or ~~and~~ up to per-halosubstituted ~~per-halo-substituted~~ C_1-C_{10} alkoxy.

46. (Previously Presented) A method of claim 38 wherein L^1 is pyridinyl substituted by $C(O)R_x$ or SO_2R_x.

47. (Previously Presented) A method of claim 39 wherein L^1 is pyridinyl substituted by $C(O)R_x$ or SO_2R_x.

48. (Currently Amended) A method of claim 46 wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 -C_{10} alkyl, C_{3-10} cycloalkyl, C_6-C_{12}aryl, ~~substituent~~ substituted C_{1-10} alkyl, ~~substituents~~ substituted C_{3-10} cycloalkyl or substituted C_6-C_{12}aryl,

where R_a or R_b is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy or C_{1-10} alkyl,

~~and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

49. (Currently Amended) A method of claim 47 wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 -C_{10} alkyl, C_{3-10} cycloalkyl or C_{6-12} aryl.

~~and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based~~

~~substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

50. (Currently Amended) A method of claim 1 wherein the compound of Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is ~~selected from the group consisting of~~

a) a basic salt ~~salts~~ of an organic acid ~~acids~~ or an ~~and~~ inorganic acid ~~acids~~ which is ~~selected from the group consisting of~~ hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or ~~and~~ mandelic acid; or ~~and~~

b) an acid salt ~~salts~~ of an organic or ~~and~~ inorganic base ~~bases~~ containing a cation which is an alkali metal cation, an alkaline earth metal cation ~~cations selected from the group consisting of alkaline cations, alkaline earth cations~~, the ammonium cation, an aliphatic substituted ammonium cation or an ~~cations and~~ aromatic substituted ammonium cation ~~cations~~.

51. Cancelled

52. (Currently Amended) A method of claim 33 wherein the compound of Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is ~~selected from the group consisting~~ of

a) a basic salt ~~salts~~ of an organic acid ~~acids and~~ or an inorganic acid ~~acids~~ which is ~~selected from the group consisting of~~ hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or ~~and~~

mandelic acid; or an ~~and~~

b) an acid salt ~~salts~~ of an organic or ~~and~~ inorganic base ~~bases~~ containing a cation which is an alkali metal cation, an alkaline earth metal cation, ~~cations selected from the group consisting of alkaline cations, alkaline earth cations~~, the ammonium cation, an aliphatic substituted ammonium cation or an ~~cations and~~ aromatic substituted ammonium cation ~~cations~~.

53. (Currently Amended) A method of claim 38 wherein the compound Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is ~~selected from the group consisting of~~

a) a basic salt ~~salts~~ of an organic acid ~~acids~~ or an ~~and~~ inorganic acid ~~acids selected from the group consisting of~~ which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or ~~and~~ mandelic acid; or ~~and~~

b) an acid salt ~~salts~~ of an organic or ~~and~~ inorganic base ~~bases~~ containing a cation which is an alkali metal cation, an alkaline earth metal cation ~~cations selected from the group consisting of alkaline cations, alkaline earth cations~~, the ammonium cation, an aliphatic substituted ammonium cation or an ~~cations and~~ aromatic substituted ammonium cation ~~cations~~.

54. (Currently Amended) A method of claim 39 wherein the compound of Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is ~~selected from the group consisting of~~

a) a basic salt ~~salts~~ of an organic acid ~~acids~~ or an and inorganic acid ~~acids~~ which is ~~selected from the group consisting of~~ hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid,

succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or ~~and~~ mandelic acid; or an ~~and~~

b) an acid salt ~~salts~~ of an organic or ~~and~~ inorganic base ~~bases~~ containing a cation which is an alkali metal cation, an alkaline earth metal cation ~~cations selected from the group consisting of alkaline cations, alkaline earth cations~~, the ammonium cation, an aliphatic substituted ammonium cation or an ~~cations and~~ aromatic substituted ammonium cation ~~cations~~.

55. Cancelled

56. Cancelled

57. Cancelled

58. Cancelled

59. Cancelled

60. Cancelled

61. Cancelled

62. Cancelled

63. Cancelled

64. Cancelled

65. Cancelled

66. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound which is a ~~selected from the group consisting of~~

3-tert butyl phenyl urea ~~ureas of Table 1 above~~;

5-tert butyl-2-methoxyphenyl urea ~~ureas of Table 2 above~~;

5-(trifluoromethyl)-2 phenyl urea ~~ureas of Table 3 above~~;

3-(trifluoromethyl) –4 chlorophenyl urea ~~ureas of Table 4 above~~;

3-(trifluoromethyl)-4-bromophenyl urea ~~ureas of Table 5 above~~; or

5-(trifluoromethyl)-4-chloro-2 methoxyphenyl urea ~~ureas of Table 6 above; and~~

~~ureas 101-103 in Table 7 above~~.

67. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound which is: ~~selected from the group consisting of~~ ~~the~~ one of the following 3-tert butyl phenyl ureas:

N-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl urea or ~~and~~
N-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl urea; or

one of the following ~~the~~ 5-*tert*-butyl-2-methoxyphenyl ureas:

N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea
or ~~and~~
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea; or

one of the following ~~the~~ 2-methoxy-5-trifluoromethyl)phenyl ureas:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea or ~~and~~
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; or

one of the following ~~the~~ 4-chloro-3-(trifluoromethyl)phenyl ureas:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea or ~~and~~
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

or one of the following ~~the~~ 4-bromo ~~romo~~-3-(trifluoromethyl)phenyl ureas:

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea or and
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

or one of the following ~~the~~ 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea or ~~and~~

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea, wherein said compound is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

68. (Currently Amended) A method for the treatment of solid cancers in a human comprising administering to a human a compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: -L-(M-L^1)$_q$, where L is a 5 or 6 membered cyclic structure bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 heteroatoms which are ~~members of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 heteroatoms which are ~~members of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur,

wherein L^1 is substituted by at least one substituent which is ~~selected from the group~~

~~consisting of~~ $-SO_2R_x$, $-C(O)R_x$ or ~~and~~ $-C(NR_y)R_z$,

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally halosubstituted, up to per-halosubstitution ~~per-halo~~,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is optionally substituted by halogen, hydroxy or ~~and~~ a carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contains~~ contain one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen;

R_x is independently chosen from R_z moieties or is ~~R_z or~~ NR_aR_b where R_a and R_b are

a) independently

i) hydrogen,

ii) a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are ~~selected from~~ N, S or ~~and~~ O and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen, or

iii). $-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen, hydroxy or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ substituted by halogen, hydroxy or a carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, or a ~~and~~ carbon based substituent ~~substituents~~ of up to 24 carbon atoms[~~,~~] which optionally ~~contain~~ contains one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen;

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are ~~selected from the group consisting of~~ halogen, up to per-halo or ~~, and~~ W_n ~~Wn~~, where n is 0-3;

wherein each W is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, or a ~~and~~ carbon based moiety ~~moieties~~ of up to 24 carbon atoms, optionally containing one or more

heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by one or more substituents which are ~~independently selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ or ~~and~~ halogen up to per-halosubstitution ~~per-halo~~; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms[~~,~~] optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen,

wherein Q is -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ or ~~and~~ $-N(R^7)(CH_2)_m-$, where m= 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are ~~members selected from the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, which is optionally substituted by halogen, up to per-halosubstitution ~~per-halo~~, and optionally substituted by Zn_1, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$ $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, or ~~and~~ a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by one or more substituents which are ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, or ~~and~~ $-NR^7C(O)OR^7$, with R^7 as defined above.

69. (Currently amended) A method for the treatment of carcinomas, myeloid disorders or adenomas in a human comprising administering to a human a compound of Formula I:

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: $-L-(M-L^1)_q$, where L

is a 5 or 6 membered cyclic structure bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 members heteroatoms which are ~~of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 heteroatoms which are ~~members of the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur,

wherein L^1 is substituted by ~~at least~~ one or more substituents ~~substituent~~ which are ~~selected from the group consisting~~ of $-SO_2R_x$, $-C(O)R_x$ or ~~and~~ $-C(NR_y)\ R_z$,

R_y is hydrogen or C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_y is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, ~~or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,~~

R_z is hydrogen C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or

O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_z is substituted it is substituted by halogen up to per-halosubstituted, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, ~~or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

R_x is independently chosen from R_z moieties or is ~~R_z or~~ NR_aR_b where R_a and R_b are

a) independently

i.) hydrogen,

ii.) C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_x is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

iii.) $-OSi(R_f)_3$ where R_f is hydrogen C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

wherein R_f is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, ~~or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S, or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ substituted by halogen, hydroxy a C_1 -C_{10} alkyl, C_1 -C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl,

substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the 5-7 member heterocyclic structure is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, ~~carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, or a ~~and~~ C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituents on the C_{1-5} divalent alkylene group is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12}

hetaryl up to per-halosubstituted heteroaryl, ~~carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are ~~selected from the group consisting of~~ halogen, up to per-halosubstitution ~~per-halo~~, ~~and~~ W_n ~~Wn~~, where n is 0-3;

wherein each W is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, ~~selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally~~

~~substituted by halogen,~~

wherein Q is -O-, -S-, -N(R^7)-, -(CH_2)$_m$-, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^7)-, -O(CH_2)$_m$- CHX^a-, -CX^a_2-, -S-(CH_2)$_m$- and -N(R^7)(CH_2)$_m$-, where m= 1-3, or ~~and~~ X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are ~~members selected from the group consisting of~~ nitrogen, oxygen or ~~and~~ sulfur, which is optionally substituted by halogen, up to per-halosubstitution ~~per-halo~~, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, -CO_2R^7, -C(O)R^7, -C(O)NR^7R^7, -NO_2, -OR^7, - SR^7 -NR^7R^7, -NR^7C(O)OR^7, -NR^7C(O)R^7, or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where Ar is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

~~and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO_2R^7, -COR^7, -C(O)NR^7R^7, -OR^7, -SR^7, -NO_2, -NR^7R^7, -NR^7C(O)R^7, and -NR^7C(O)OR^7, with R^7 as defined above.~~

70. (Previously Presented) A method as in claim 38 for the treatment of carcinomas, myleoid disorders or adenomas.

71. (Previously Presented) A method as in claim 39 for the treatment of carcinomas, myleoid disorders or adenomas.

72. (Previously Presented) A method as in claim 50 for the treatment of carcinomas, myleoid disorders or adenomas.

73. (Previously Presented) A method as in claim 67 for the treatment of carcinomas, myleoid disorders or adenomas.

74. (Previously Presented) A method as in claim 1 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon mediated by RAF kinase.

75. (Previously Presented) A method as in claim 38 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

76. (Previously Presented) A method as in claim 39 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

77. (Previously Presented) A method as in claim 50 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

78. (Previously Presented) A method as in claim 67 for the treatment of carcinoma of

the lung, pancreas, thyroid, bladder or colon.

79. (Previously Presented) A method as in claim 1 for the treatment of myeloid leukemia or villous colon adenomas mediated by RAF kinase.

80. (Previously Presented) A method as in claim 28 for the treatment of myeloid leukemia or villous colon adenomas.

81. (Previously Presented) A method as in claim 39 for the treatment of myeloid leukemia or villous colon adenomas.

82. (Previously Presented) A method as in claim 50 for the treatment of myeloid leukemia or villous colon adenomas.

83. (Previously Presented) A method as in claim 67 for the treatment of myeloid leukemia or villous colon adenomas.

Please add the following claims:

--84. (New) A method as in claim 1 wherein said composition of Formula I is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

85. (New) A method as in claim 3 wherein:

R_y, R_z, R_a, and R^7 are each independently hydrogen, C_{1-10} alkyl optionally

substituted by halogen up to per-halosubstitution or C_{1-10} alkoxy optionally substituted by halogen up to per-halosubstitution.

86. (New) A method as in claim 85 wherein said substituted cyclic moiety L^1 is pyridinyl.

87. (New) A method of claim 8 wherein L^1 is pyridyl substituted by $C(O)R_x$ wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or C_1-C_{10} alkyl.

88. (New) A method for the treatment of cancerous cell growth in a human or other mammal comprising administering to a human or other mammal in need thereof:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

89. (New) A method for the treatment of cancerous cell growth mediated by raf kinase in a human or other mammal comprising administering to a human or other mammal in need thereof:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

90. (New) A method for the treatment of a raf mediated disorder in a human or other mammal which comprises administering to a human or other mammal in need thereof;

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

91. (New) A method for treatment of a raf mediated disorder in a human or other mammal, comprising administering to a human or other mammal in need thereof a pharmaceutical composition comprising a compound of Formula I:

A-D-B (I)

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula:

-L-M-L^1

wherein L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, C_1-C_5 alkyl, C_1-C_5 haloalkyl up to per-halosubstituted, C_1-C_3 alkoxy, C_1-C_3 haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano or nitro;

(ii) a 5 membered monocyclic heteroaryl group, having 1-2 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, C_1-C_5 haloalkyl up to per-halosubstitution, C_1-C_3 haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, or nitro; or

(iii) a 6 membered monocyclic heteroaryl group having 1-4 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents, which are, independently, C_1-C_5 alkyl, C_1-C_5 haloalkyl up to per-halosubstitution, C_1-C_3 alkoxy, C_1-C_3 haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano or nitro;

L^1 comprises a substitution cyclic moiety which is

(i) phenyl, optionally substituted with 1-3 substituents which are independently, R^7, OR^7,

$NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are independently N, S or O, optionally substituted with 1-3 substituents which are independently R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms which are independently, N, S or O, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(v) saturated and partially saturated C_3-C_6 monocyclic carbocyclic moieties optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(vi) saturated and partially saturated C_8-C_{10} bicyclic carbocyclic moieties, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(vii) saturated and partially saturated 5 and 6 membered monocyclic heterocyclic moieties, having 1-3 heteroatoms which are independently, N, S or O, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro; or

(viii) saturated and partially saturated 8 to 10 membered bicyclic heterocyclic moieties, having 1-6 heteroatoms which are independently, N, S or O, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

wherein L^1 is substituted by one or more substituents which are $-SO_2R_x$, $-C(O)R_x$ or

$-C(NR_y)\ R_z$,

wherein R_z is

a) independently hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 which are N, S or O heteroatoms, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3 -C_{12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{7-24} alkaryl , C_{7-24} aralkyl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_6-C_{14} aryl, substituted C_3 -C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} alkaryl or substituted C_7-C_{24} aralkyl

where R_z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl up to per-halosubstituted per-halo cycloalkyl having 0-3 heteroatoms which are N, S or O, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted hetaryl having 1-3 heteroatoms which are N, S or O, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted aralkyl, or halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted alkaryl,

wherein R_x is independently chosen from R_z moieties or is NR_aR_b and R_a and R_b are

a) independently hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 which are N, S or O heteroatoms, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3 -C_{12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{7-24} alkaryl , C_{7-24} aralkyl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_6-C_{14} aryl, substituted C_3 -C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} alkaryl or substituted C_7-C_{24} aralkyl,

where R_a or R_b is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl

up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl up to per-halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted hetaryl having 1-3 heteroatoms which are N, S or O, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted aralkyl, or halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted alkaryl, or

b) combined together to form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O, optionally substituted by halogen hydroxy or C_{1-10} alkyl; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L^1 to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are halogen hydroxy, or C_{1-10} alkyl;

wherein M is one or more bridging groups which are -O-, -S-, -N(R^7)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^7)-, -O$(CH_2)_m$- CHX^a-, -CX^a_2-, -S-$(CH_2)_m$- or -N(R^7)$(CH_2)_m$-, where m= 1-3, and X^a is halogen and

B is:

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$ halogen, cyano, or nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro;

each R_y is independently

(a) hydrogen,

(b) C_1-C_6 alkyl, optionally substituted with halogen up to per-halosubstitution,

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 halogen substituents,

(d) C_3-C_6 cyclic alkyl, optionally substituted with 1-3 halogen substituents,

(e) phenyl, optionally substituted with 1-3 halogen substituents,

(f) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 halogen substituents, or

(g) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 halogen substituents,

each R^7 and $R^{7'}$, is independently

(a) hydrogen,

(b) C_1-C_6 alkyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy or hydroxy ;

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 substituents which are, independently, C_1-C_5, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen;

(d) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted

C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(f) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen; and

(g) up to per–halosubstituted C_1-C_5, and where not per-halosubstituted, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy or hydroxy.

92. (New) A method as in claim 91 wherein M is one or more bridging groups is -O-, -S- , -N(R^7)-, -C(O)-, -CH(OH)-, -(CH_2)O-, -(CH_2)S-, -(CH_2)N(R^7)-, -O(CH_2)- , -CHF-, -CF_2-, -S-(CH_2)- and -N(R^7)(CH_2)-, -C(O)CH_2-, -CH_2OC(O)-, -C(O)OCH_2-, -C(O)N(R^7)CH_2-, -N(R^7)C(O)CH_2-, or -N(R^7)C(O) OCH_2-, where R^7 is as defined in claim 91.

93. (New) A method as in claim 91 wherein B of Formula I is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(iii) pyrimidinyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro.

94. (New) A method as in claim 91 wherein B of Formula I is phenyl, or pyridinyl l,

substituted 1 to 3 times by one or more substituents which are independently -CN, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -OH, up to per-halosubstituted C_1-C_6 alkyl, up to per halosubstituted C_1-C_6 alkoxy or phenyl substituted by halogen up to per-halosubstitution.

95. (New) A method as in claim 94, wherein L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R^1, OR^1, NR^1R^2, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, or nitro.

96. (New) A method as in claim 91, wherein L^1 is phenyl, pyridinyl or pyrimidinyl.

97. (New) A method as in claim 93 wherein L^1 is phenyl, pyridinyl or pyrimidinyl.

98. (New A method as in claim 94, wherein L^1 is phenyl or pyridinyl.

99. (New) A method as in claim 95, wherein L^1 is phenyl or pyridinyl.

100. (New) A method as in claim 97, wherein M is -O-, -S- , -C(O)-, -CH(OH)-, -(CH_2)O-, -(CH_2)S-, -O(CH_2)- , -S-(CH_2)- , -CHF-, -CF_2- or -C(O)CH_2-.

101. (New) A method as in claim 98, wherein M is -O-, -S-, -C(O)-, -CH(OH)-, -(CH_2)O-, -(CH_2)S-, -O(CH_2)- , -CHF-, -CF_2-, -S-(CH_2)- or -C(O)CH_2- .

102. (New) A method as in claim 99, wherein M is -O-, -S- , $-(CH_2)O-$, $-(CH_2)S-$, $-O(CH_2)-$, -CHF-, $-CF_2-$, $-S-(CH_2)-$ or $-C(O)CH_2-$.

103. (New) A method as in claim 91 wherein L^1 is substituted by $-C(O)R_x$.

104. (New) A method of claim 100 wherein L^1 is substituted by $-C(O)R_x$ wherein R_x is NR_aR_b.

105. (New) A method as in claim 101 wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy.

106. (New) A method as in compound of claim 102 wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 –C_6 alkyl or C_1 –C_6 alkoxy.

107. (New) A method for the treatment of a raf mediated disorder in a human or other mammal, comprising administering to a human or other mammal in need thereof, a pharmaceutical composition comprising a compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is of the formula:

$-L-M-L^1$,

where L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, C_1-C_5 haloalkyl up to per-halosubstituted alkyl, C_1-C_3 alkoxy, hydroxy, amino, C_1-

C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, C_1-C_5 haloalkyl up to per-halosubstituted alkyl, C_1-C_3 alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, or nitro; and

M is one or more bridging groups which are -O-, -S-, -N(R^7)-, -(CH_2)$_m$-, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^7)-, -O(CH_2)$_m$- CHX^a-, -CX^a_2-, -S-(CH_2)$_m$- or -N(R^7)(CH_2)$_m$-, where each m is independently an integer of from 1-3, X^a is halogen, and

L^1 comprises a substituted cyclic moiety which is:

(i) naphthyl, optionally substituted with 1-3 substituents which are, independently, fR^7, OR^7, N$R^7R^{7'}$, C(O)R^7, C(O)OR^7, C(O)N$R^7R^{7'}$, NR^7C(O)$R^{7'}$, NR^7C(O)O$R^{7'}$, halogen, cyano or nitro;

(ii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, N$R^7R^{7'}$, C(O)R^7, C(O)OR^7, C(O)N$R^7R^{7'}$, NR^7C(O)$R^{7'}$, NR^7C(O)O$R^{7'}$, halogen, cyano or nitro;

(iii) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms, which are, independently, N, S or O, optionally substituted with 1-3 substituents, which are, independently, R^7, OR^7, N$R^7R^{7'}$, C(O)R^7, C(O)OR^7, C(O)N$R^7R^{7'}$, NR^7C(O)$R^{7'}$, NR^7C(O)O$R^{7'}$, halogen, cyano or nitro;

wherein L^1 is substituted by one or more substituents which are -SO_2R_x, -C(O)R_x or -C(NR_y) R_z,

wherein R_x independently chosen from the moieties of R_z or N$R_a$$R_b$ and R_a and R_b are independently chosen from the moieties of R_z;

and

B is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, f R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro;

each R_y is independently

(a) hydrogen,

(b) C_1-C_6 alkyl, optionally substituted with halogen up to per-halosubstitution,

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 halogen substituents,

(d) C_3-C_6 cyclic alkyl, optionally substituted with 1-3 halogen substituents,

(e) phenyl, optionally substituted with 1-3 halogen substituents,

(f) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 halogen substituents, or

(g) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 halogen substituents,

each R^7, $R^{7'}$and R_z is independently

(a) hydrogen,

(b) C_1-C_6 optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy or hydroxy ;

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen;

(d) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(f) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 substituents, which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen; or

(g) up to per–halosubstituted C_1-C_5 alkyl, and where not per-halosubstituted, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy or hydroxy.

108. (New) A method as in claim 107 wherein substituents for B and L and additional substituents for L^1, one C_1-C_6 alkyl up to per-halosubstituted C_1-C_6 alkyl, CN, OH, halogen, C_1-C_6 alkoxy or up to per-halosubstituted C_1-C_6 alkoxy.

109. (New) A method of claim 107 wherein L^1 is pyridyl and is substituted by $C(O)R_x$ or $SO_2\ NR_aR_b$.

110. (New) A method of claim 91 wherein a

pharmaceutically acceptable salt of a compound of Formula I of claim 91 is used which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid,

lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

111. (New) A method of claim 107 wherein a

pharmaceutically acceptable salt of a compound Formula I of claim 61 which is selected from the group consisting of

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

112. (New) A method of claim 91 wherein the substituted or unsubstituted monocyclic heteroaryl groups of B, L and L^1 are, independently,

2- and 3-furyl,

2- and 3-thienyl,

2- and 4-triazinyl,

1-, 2- and 3-pyrrolyl,

1-, 2-, 4- and 5-imidazolyl,

1-, 3-, 4- and 5-pyrazolyl,

2-, 4- and 5-oxazolyl,

3-, 4- and 5-isoxazolyl,

2-, 4- and 5-thiazolyl,

3-, 4- and 5-isothiazolyl,

2-, 3- and 4-pyridyl,

2-, 4-, 5- and 6-pyrimidinyl,

1,2,3-triazol-1-, -4- and –5-yl,

1,2,4-triazol-1-, -3- and –5-yl,

1- and 5-tetrazolyl,

1,2,3-oxadiazol-4- and –5-yl,

1,2,4-oxadiazol-3- and –5-yl,

1,3,4-thiadiazol-2- and –5-yl,

1,2,4-oxadiazol-3- and –5-yl,

1,3,4-thiadiazol-2- and –5-yl,

1,3,4-thiadiazol-3- and –5-yl,

1,2,3-thiadiazol-4- and –5-yl,

2-, 3-, 4-, 5- and 6-2H-thiopyranyl,

2-, 3- and 4-4H-thiopyranyl,

3- and 4-pyridazinyl, or

2-,3-pyrazinyl.

113. (New) A compound of claim 91 wherein the substituted or unsubstituted bicyclic heteroaryl groups of B and L^1 are, independently:

2-, 3-, 4-, 5-, 6- and 7-benzofuryl,
2-, 3-, 4-, 5-, 6- and 7-benzothienyl,
1-, 2-, 3-, 4-, 5-, 6- and 7-indolyl,
1-, 2-, 4- and 5-benzimidazolyl,
1-, 3-, 4-, 5-, 6- and 7-benzopyrazolyl,
2-, 4-, 5-, 6- and 7-benzoxazolyl,
3-, 4-, 5- 6- and 7-benzisoxazolyl,
1-, 3-, 4-, 5-, 6- and 7-benzothiazolyl,
2-, 4-, 5-, 6- and 7-benzisothiazolyl,
2-, 4-, 5-, 6- and 7-benz-1,3-oxadiazolyl,
2-, 3-, 4-, 5-, 6-, 7- and 8-quinolinyl,
1-, 3-, 4-, 5-, 6-, 7-, and 8- isoquinolinyl,
2-, 4-, 5-, 6-, 7- and 8-quinazolinyl,
tetrahydroquinolinyl,
tetrahydroisoquinolinyl,
dihydrobenzofuryl,
pyrazolo[3,4-b]pyrimidinyl,
purinyl,
benzodiazine,
pterindinyl,
pyrrolo[2,3-b]pyridinyl,
pyrazolo[3,4-b]pyridinyl,
oxazo[4,5-b]pyridinyl,
imidazo[4,5-b]pyridinyl,
cyclopentenopyridine,
cyclohexanopyridine,
cyclopentanopyrimidine,

cyclohexanopyrimidine,
cyclcopentanopyrazine,
cyclohexanopyrazine,
cyclopentanopyridiazine,
cyclohexanopyridazine,
cyclopentanoimidazole,
cyclohexanoimidazole,
cyclopentanothiophen or
cyclohexanothiophene.

114. (New) A method of claim 91 wherein the substituted 5 and 6 membered monocyclic heteroaryl moieties of B, L and L^1 are independently

5-methyl-2-thienyl,
4-methyl-2-thienyl,
1-methyl-3-pyrolyl,
1-methyl-3-pyrazolyl,
5-methyl-2-thiazolyl, or
5-methyl-1,2,4-thiadiazol-2-yl; or

the substituted phenyl and naphthyl groups of B, L and L^1 are independently

tetrahydronaphthyl,
indanyl,
indenyl,
benzocyclobutanyl,
benzocycloheptanyl or
benzocycloheptenyl;

the partially saturated monocyclic heterocyclic moieties of B, L and L^1 are independently:

dihydropyranyl,
dihydrofuranyl,
dihydrothienyl,

dihydropiperidinyl or
dihydropyrimidonyl.

115. (New) A method of claim 91 wherein the structures of B, L and L^1 are each,

phenyl, furyl,
oxadiazolyl, oxazolyl, isooxazolyl,
pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl,
tetrazolyl,
thiadiazolyl, thiazolyl or thienyl and
the structures of B and L^1 are additionally naphthyl, isoindolinyl, quinolinyl or isoquinolinyl.

116. (New) A method of claim 115 wherein the substituents of the substituted structures of L are methyl, triflouromethyl, ethyl, n-propyl, n-butyl, n-pentyl, i-propyl, t-butyl, methoxy, ethoxy, propoxy, Cl, Br, F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino or diethylamino.

117. (New) A metthod of claim 115 wherein the substituents of the substituted structures of B and L^1 are methyl, triflouromethyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl, *tert*-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, Cl, Br and F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino or diethylamino.

118. (New) A method of claim 115 wherein the substituents of the substituted structures of B and L^1 are each, independently, selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, chlorophenyl, dichlorophenyl, bromophenyl, dibromophenyl, chloropyridinyl, bromopyridinyl, dichloropyridinyl, dibromopyridinyl methylphenyl, methylpyridinyl quinolinyl, isoquinolinyl, isoindolinyl, pyrazinyl, pyridazinyl, pyrrolinyl, imidazolinyl, thienyl, furyl,

isoxazolinyl, isothiazolinyl, benzopyridinyl, benzothiazolyl,

C_1-C_5 acyl;

$NH(C_1$-C_5 alkyl, phenyl or pyridinyl);

$N(C_1$-C_5 alkyl)(C_1-C_5 alkyl, phenyl or pyridinyl);

$N(C_1$-C_3 alkyl) $SO_2(C_1$-C_5 alkyl);

$CO(C_1$-C_6 alkyl or phenyl);

C(O)H;

$C(O)O(C_1$-C_6 alkyl or phenyl);

C(O)OH;

$C(O)NH_2$;

$C(O)NH(C_1$-C_6 alkyl or phenyl) ;

$C(O)N(C_1$-C_6 alkyl or phenyl)(C_1-C_6 alkyl, phenyl or pyridinyl);

$C(NCH_3)CH_3$;

$NHC(O)(C_1$-C_6 alkyl or phenyl) or

$N(C_1$-C_5 alkyl,)$C(O)(C_1$-C_5 alkyl).

119. (New) A method as in claim 91 wherein B, L and L^1 of the compound of Formula I or the pharmaceutically acceptable salt thereof follow one of the following of combinations:

B= phenyl, L=phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B= phenyl, L=pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B=phenyl, L = naphthyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B=pyridinyl, L= phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B=pyridinyl, L= pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B =isoquinolinyl, L= phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B= isoquinolinyl, L= pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,

B= quinolinyl, L= phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl, or

B= quinolinyl, L= pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl.

120. (New) A method as in claim 119 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

121. (New) A method for the treatment of a raf mediated disorder in a human or other mammal, comprising administering to a human or other mammal in need thereof, a pharmaceutical composition comprising a tosylate salt of

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea or

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.--